PCSK9 Antagonist Antibodies for Variable Statin Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperlipidemia and hypercholesterolemia, such as statin therapy, are not fully effective for all patients, and there is a need for more targeted interventions to regulate LDL receptor levels and lower plasma cholesterol.
Innovation Solution
Development of PCSK9 antagonists, specifically antibodies and fragments, that bind to PCSK9 with high affinity and specificity, including antibodies with engineered VH and VL domains, to inhibit PCSK9 activity and increase LDL receptor expression, potentially combined with statins or ANGPTL3 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statin therapy is used to treat hyperlipidemia, then LDL cholesterol levels are reduced, but the treatment is not fully effective for all patients
Solution Approach 1:
The patent introduces PCSK9 antagonists as intermediary molecules that mediate between the treatment goal and the biological system. These antagonists specifically bind to PCSK9, preventing it from degrading LDL receptors, thereby enhancing the effectiveness of lipid-lowering therapy in patients who respond inadequately to statins alone
Solution Approach 2:
The patent employs parameter changes by modifying the biological system's response to lipid-lowering therapy through PCSK9 inhibition. By changing the activity level of PCSK9 (from active to inhibited), the system achieves enhanced LDL receptor expression and improved cholesterol reduction efficacy in patients with varying responses to conventional therapy
2Quantity of substance
If PCSK9 levels are increased, then LDL receptor levels in the liver decrease, but this leads to increased plasma cholesterol
Solution Approach 1:
The patent applies preliminary anti-action by using PCSK9 antagonists to preemptively block PCSK9 before it can degrade LDL receptors. This preventive inhibition prevents the harmful cascade that would otherwise lead to reduced LDL receptor levels and subsequently elevated plasma cholesterol
Solution Approach 2:
The patent converts the harmful effect of PCSK9 (which degrades LDL receptors and increases cholesterol) into a beneficial therapeutic target. By specifically antagonizing PCSK9, the treatment transforms the problematic PCSK9-LDLR interaction into a controlled mechanism that enhances LDL receptor stability and reduces plasma cholesterol
3Reliability
If PCSK9 antagonists are developed with high affinity and specificity, then LDL receptor expression increases, but the antibody structure becomes more complex
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional domains (VH and VL domains with specific CDR regions). This segmentation allows for targeted optimization of affinity and specificity in the variable regions while maintaining standardized constant regions, thereby managing overall structural complexity
Solution Approach 2:
The patent implements local quality by engineering specific regions of the antibody (particularly the CDR3 loops in VH and VL domains) with enhanced affinity and specificity for PCSK9. This localized optimization allows high-performance binding without requiring complex modifications throughout the entire antibody structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PCSK9 antagonists effectively reduce non-HDL cholesterol levels and enhance LDL uptake, providing a therapeutic option for hyperlipidemia and hypercholesterolemia that complements existing treatments.
Implementation Method 1
a binding site which specifically binds to Proprotein Convertase Subtilisin Kexin type 9 (PCSK9)
Data Source
AI summary
The invention relates to Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.